Non-exclusive rebate agreement for Aclidiniumbromid
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Aclidiniumbromid (ATC-Code nach WHO: R03BB05)
Opportunity Score
Why this score?
Opportunity
46 / 100
Complexity
58 / 100
Risk factors
The notice says participation documents must be submitted via the DTVP communication function, while also stating that...
Only the first participation deadline is explicitly stated in the extracted text; further deadlines are in a missing at...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Feb 29, 2028
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Feb 2028
- Non-exclusive rebate agreements for pharmaceutical products containing Aclidiniumbromid (ATC R03BB05).
- Open-House model: any interested eligible pharmaceutical company may join during the participation period.
Show full summary
This is an Open-House supply arrangement for non-exclusive pharmaceutical rebate agreements under §130a(8) SGB V for the active substance Aclidiniumbromid (ATC R03BB05). The lead buyer is AOK PLUS. No contract value is stated; demand and minimum purchase volumes are explicitly not guaranteed. Participation is open to all eligible pharmaceutical companies during the participation period, with electronic communication via DTVP and no electronic submission via the bidder tool. The notice and XML contain some inconsistencies on dates and submission mechanics, but the core scope and Open-House nature are clear.
Risks
The notice says participation documents must be submitted via the DTVP communication function, while also stating that...
Only the first participation deadline is explicitly stated in the extracted text; further deadlines are in a missing at...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Applicant must be a pharmaceutical company within the meaning of § 4(18) AMG for the offered medicinal products.
Eligibility
- Submission of the completed declaration on the absence of exclusion grounds is required.
Administrative
- The company must meet the participation requirements in the documents 'Anschreiben' and 'Erläuterungen der Vertragsbedingungen'.
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Non-exclusive rebate agreement for Aclidiniumbromid
Open-House supply lot for non-exclusive pharmaceutical rebate agreements for medicines containing Aclidiniumbromid (ATC R03BB05). Scope is limited to the named active substance; no exclusivity, no individual negotiations, and no guaranteed minimum purchase volume. Place of performance is Dresden, Germany, with performance covering Germany and the federal states of Saxony and Thuringia as stated in the XML notice.
Location
Duration
Category
Deadline
Award details
Siehe Kurzbeschreibung
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Aclidiniumbromid (ATC-Code nach WHO: R03BB05)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 23 Dec 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 862508-2025
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
46 / 100
Complexity
58 / 100
Risk factors
The notice says participation documents must be submitted via the DTVP communication function, while also stating that...
Only the first participation deadline is explicitly stated in the extracted text; further deadlines are in a missing at...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications